QS Investors LLC Sells 404 Shares of Becton Dickinson and Co (BDX)

Share on StockTwits

QS Investors LLC cut its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 3.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,721 shares of the medical instruments supplier’s stock after selling 404 shares during the quarter. QS Investors LLC’s holdings in Becton Dickinson and were worth $2,641,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. James Hambro & Partners boosted its stake in shares of Becton Dickinson and by 57.0% in the 4th quarter. James Hambro & Partners now owns 112,259 shares of the medical instruments supplier’s stock worth $25,290,000 after buying an additional 40,750 shares during the last quarter. Nippon Life Global Investors Americas Inc. boosted its stake in shares of Becton Dickinson and by 10.4% in the 4th quarter. Nippon Life Global Investors Americas Inc. now owns 38,970 shares of the medical instruments supplier’s stock worth $8,781,000 after buying an additional 3,660 shares during the last quarter. Banque Pictet & Cie SA boosted its stake in shares of Becton Dickinson and by 25.0% in the 4th quarter. Banque Pictet & Cie SA now owns 38,524 shares of the medical instruments supplier’s stock worth $8,680,000 after buying an additional 7,700 shares during the last quarter. Gofen & Glossberg LLC IL boosted its stake in shares of Becton Dickinson and by 5.5% in the 4th quarter. Gofen & Glossberg LLC IL now owns 43,228 shares of the medical instruments supplier’s stock worth $9,740,000 after buying an additional 2,261 shares during the last quarter. Finally, Granite Investment Advisors LLC boosted its stake in shares of Becton Dickinson and by 81.9% in the 4th quarter. Granite Investment Advisors LLC now owns 31,769 shares of the medical instruments supplier’s stock worth $7,158,000 after buying an additional 14,300 shares during the last quarter. 85.46% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts recently commented on the company. TheStreet upgraded Becton Dickinson and from a “c+” rating to an “a” rating in a research note on Tuesday, February 5th. Piper Jaffray Companies upped their price objective on Becton Dickinson and to $274.00 and gave the company an “overweight” rating in a research note on Tuesday, February 5th. Zacks Investment Research raised shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $243.00 target price on the stock in a report on Tuesday, January 8th. Morgan Stanley lowered their target price on shares of Becton Dickinson and from $265.00 to $240.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 2nd. Finally, Citigroup lowered their target price on shares of Becton Dickinson and from $279.00 to $256.00 and set a “buy” rating on the stock in a report on Wednesday, January 2nd. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Becton Dickinson and currently has an average rating of “Buy” and a consensus price target of $253.55.

Becton Dickinson and stock opened at $253.92 on Monday. The firm has a market capitalization of $68.32 billion, a PE ratio of 23.06, a PEG ratio of 1.76 and a beta of 1.21. Becton Dickinson and Co has a fifty-two week low of $208.62 and a fifty-two week high of $265.87. The company has a current ratio of 0.97, a quick ratio of 0.62 and a debt-to-equity ratio of 0.83.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.58 by $0.12. The firm had revenue of $4.16 billion for the quarter, compared to analysts’ expectations of $4.10 billion. Becton Dickinson and had a net margin of 5.69% and a return on equity of 14.65%. The business’s quarterly revenue was up 35.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.48 earnings per share. As a group, sell-side analysts anticipate that Becton Dickinson and Co will post 12.1 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, March 29th. Stockholders of record on Friday, March 8th will be issued a $0.77 dividend. The ex-dividend date is Thursday, March 7th. This represents a $3.08 annualized dividend and a dividend yield of 1.21%. Becton Dickinson and’s payout ratio is currently 27.97%.

In other news, EVP Ribo Alberto Mas sold 4,808 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $255.03, for a total value of $1,226,184.24. Following the transaction, the executive vice president now owns 22,476 shares of the company’s stock, valued at $5,732,054.28. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Vincent A. Forlenza sold 3,123 shares of the stock in a transaction on Monday, March 4th. The shares were sold at an average price of $255.03, for a total value of $796,458.69. Following the completion of the transaction, the chief executive officer now directly owns 215,372 shares in the company, valued at approximately $54,926,321.16. The disclosure for this sale can be found here. In the last ninety days, insiders sold 19,271 shares of company stock worth $4,862,179. Insiders own 0.12% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Week Herald and is owned by of Week Herald. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://weekherald.com/2019/03/18/qs-investors-llc-sells-404-shares-of-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

See Also: Should you buy a closed-end mutual fund?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.